Investor Presentaiton

Consistent Strong Growth Accelerating Revenue Growth ($ in millions) Improving Gross Margin & Profit ($ in millions) LTV/CAC:1 5x $12.7 $11.8 Payback Period:² $10.8 45% YOY ~13 months $9.6 $8.8 $7.9 $7.3 $7.0 $6.6 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 $6.2 $5.8 54% YOY $5.1 $4.4 $4.0 $3.6 $3.1 $3.2 $2.9 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 $26.3M net public financing³ (Nov'23) to drive incremental growth by expanding Augmedix's commercial team, accelerating automation initiatives, and advancing efforts to create an open ecosystem of integrations and partnerships Note: Fiscal years are audited through December 31, 2022. Quarterly results are unaudited. 1. 2. 23 3. LTM to 12/31/2023. The Lifetime Value (LTV) of Augmedix Live is calculated by ARPU / (Annual Churn Percentage) x expected contribution margin. Customer Acquisition Cost (CAC) is the sales and marketing spend in the previous quarter divided by number of new clinicians sold in the most recent quarter plus the onboarding costs in the most recent quarter divided by the number of go lives in the most recent quarter. LTM to 12/31/2023. Payback period in months is calculated by CAC divided by the expected contribution profit in the first-year x 12. Includes lead investment from existing shareholders HCA Healthcare, Inc. (NYSE: HCA) and Redmile Group, LLC. 18

View entire presentation